3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
3
Neoplasms
3
Lymphoma
3
Leukemia
3
Infections
3
Lymphoma, Non-Hodgkin
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Febrile Neutropenia
1
Cystectomy
1
Colorectal Neoplasms
1
Agammaglobulinemia
1
Interventions
Cyclophosphamide
22
fludarabine
20
venetoclax
8
Whole-Body Irradiation
8
Mycophenolic Acid
8
Standard of Care
6
Mesna
6
Melphalan
6
Azacitidine
6
fludarabine phosphate
5
Sirolimus
5
thymoglobulin
4
Thiotepa
4
Tacrolimus
4
Specimen Handling
4
Filgrastim
4
Cytarabine
4
entrectinib
3
daratumumab
3
cobimetinib
3
alectinib
3
Vemurafenib
3
Surveys and Questionnaires
3
Rituximab
3
Practice Guidelines as Topic
3
Palliative Care
3
Granulocyte Colony-Stimulating Factor
3
Busulfan
3
Bortezomib
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hematologic Neoplasms
×
Ciprofloxacin
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled